2014-07-24T14:53:36-05:00 2013-08-31 KPMG LLP 550 S Hope St Suite 1500 Los Angeles CA 90071 990 2012-09-01 453682796 California Institute for Biomedical research % AMANDA ARELLANO CALI 8582421029 11119 N TORREY PINES RD Suite 100 LA JOLLA CA 92037 MATTHEW TREMBLAY 8582421029 2014-07-14 true 2139724000 2012 2015-11-30 17:44:51Z PETER G SCHULTZ PhD 11119 NTORREY PINES RD 100 LA JOLLA CA 92037 13622921 false X www.calibr.org X 2011 CA The California Institute for Biomedical Research (Calibr) accelerates the translation of basic biomedical research to new medicines for unmet medical needs. 5 3 54 0 0 120000 21590 6645043 13599178 1984 2153 0 0 6767027 13622921 0 0 0 0 606246 4259827 0 0 0 1966704 7430693 2572950 11690520 4194077 1932401 6014072 8092145 1819995 1965667 4194077 6126478 X OUR MISSION IS TO BUILD A UNIQUE INSTITUTE THAT BRIDGES BASIC RESEARCH AND DRUG DISCOVERY, AND THAT ATTRACTS THE BEST AND BRIGHTEST SCIENTISTS, PHYSICIANS AND STUDENTS TO WORK TOGETHER SYNERGISTICALLY TO FIND CURSES FOR NEGLECTED HUMAN DISEASES. THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (CALIBR) IS A BIOMEDICAL RESEARCH ORGANIZATION LOCATED IN SAN DIEGO, CALIFORNIA. CALIBR BRIDGES THE GAP BETWEEN BASIC BIOMEDICAL RESEARCH AND THE CLINICAL APPLICATION OF RESEARCH DISCOVERIES TO HUMAN DISEASE. CALIBR COMMITS SUBSTANTIALLY ALL OF ITS RESOURCES TO BIOMEDICAL RESEARCH ACTIVITIES. CALIBR'S RESEARCH AND WORK WILL CATALYZE THE TRANSLATION OF DISCOVERIES BY SCIENTISTS AT SCRIPPS RESEARCH INSTITUTE, AND OTHER SAN DIEGO RESEARCH INSTITUTES (SUCH AS U.C. SAN DIEGO AND SALK INSTITUTE), AS WELL AS OTHER MAJOR RESEARCH INSTITUTES THROUGHOUT THE WORLD, INTO POTENTIAL NEW THERAPIES FOR MANY LIFE THREATENING AND DEBILITATING DISEASES. THESE DISEASES INCLUDE ORPHAN DISEASES, DEGENERATIVE DISEASES false false 9968839 0 13599178 RESEARCH GRANTS AND CONTRACTS ARE RECEIVED FROM PUBLIC ANDPRIVATE INSTITUTIONS AND ARE USED TO CONDUCT BIOMEDICAL RESEARCH. IN THE CURRENT FISCAL YEAR, CALIBR CONDUCTED RESEARCH THROUGH A PRIVATE COLLABORATION AGREEMENT ON AUTOIMMUNE AND INFLAMMATORY DISEASES, CANCER BIOLOGY, CARDIOVASCULAR METABOLIC DISEASES AND NEUROBIOLOGY. IN ADDITION, IT CONDUCTED RESEARCH FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY, JUVENILE DIABETES, and TB DRUG DEVELOPMENT. 0 9968839 true true false false false false false false false false true false false false true false false false false false false false false false false false false false false false false false false false false false false true false false false false false false false false false true 9 0 true 54 true false false false false false false false false false false X 5 3 true false false false false false false true true false false true true true true true true false false false CA X AMANDA ARELLANO 8582421029 11119 N TORREY PINES RD SUITE 10 LA JOLLA CA 92037 Peter G Schultz phd 20.0 0.0 X X 24960 0 0 Isy Goldwasser 1.0 0.0 X X 0 0 0 Paul Schimmel phd 1.0 0.0 X 0 0 0 John Diekman phd 1.0 0.0 X X 0 0 0 Rick Lifton 1.0 0.0 X 0 0 0 AMIT BHATIA 40.0 0.0 X 93078 0 4200 118038 0 4200 0 false false false 0 X 21590 14900 21590 MEDICAL RESEARCH 541700 13599178 13599178 13599178 2153 2153 0 0 0 0 0 0 0 0 0 0 13622921 13599178 2153 0 0 0 0 227345 227345 0 3368099 3112658 255441 0 361043 318316 42727 303340 289516 13824 0 76330 76330 3000 3000 0 0 0 215826 35612 180214 0 257778 25935 231843 363983 195403 168580 0 1264545 1150736 113809 23761 23761 0 0 0 0 746465 741114 5351 8953 8953 LAB SUPPLIES 2501801 2501801 MINOR FURNITURE AND EQUIPMENT 541135 267935 273200 OUTSOURCED RESEARCH & SERVICE 517019 480659 36360 SERVICE AGREEMENTS 325086 324106 980 585011 501287 83724 11690520 9968839 1721681 0 0 0 2008160 2101436 0 206884 0 0 0 0 0 0 0 0 0 0 212853 222367 6510317 965521 3793059 5544796 0 0 0 0 0 0 0 16662 0 0 6014072 8092145 482609 656280 0 0 1054956 695596 0 0 0 0 0 0 0 0 0 0 282430 613791 1819995 1965667 X 4194077 6126478 0 0 0 0 4194077 6126478 6014072 8092145 1932401 X false false false X 0 0 0 120000 21590 141590 0 0 0 0 0 120000 21590 141590 129071 12519 1984 2153 4137 0 0 145727 20741272 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 6510317 965521 5544796 5544796 0 DEFERRED RENT 613791 613791 13622921 13622921 13622921 11690520 11690520 11690520 AMBRX INC PETER SCHULTZ AND JOHN 2400000 COLLABORATIVE LICENSE AGREEMNT false BUSINESS RELATIONSHIP PART VI, SECTION A, LINE 2 President and board member Peter Schultz serves on a number of other corporate boards with board members John Diekman and Isy Goldwasser. FORM 990 REVIEW PROCESS PART VI, SECTION B, LINE 11B INFORMATION USED TO PREPARE THE FORM 990 WAS COMPILED BY CALIBR'S PERSONNEL. THE RETURN WAS PREPARED WITH THE ASSISTANCE OF ITS PUBLIC ACCOUNTING FIRM. THE FORM 990 WAS REVIEWED BY CALIBR'S AUDIT COMMITTEE, WHICH HAS AUTHORITY AND OVERSIGHT OF CALIBR'S AUDIT AND TAX PREPARATION. A COMPLETE COPY OF THE FORM 990 WAS PROVIDED TO THE FULL BOARD AFTER REVIEW BY THE AUDIT COMMITTEE AND PRIOR TO FILING WITH THE IRS. CONFLICT OF INTEREST POLICY PART VI, SECTION B, LINE 12C ON AN ANNUAL BASIS, CALIBR DISTRIBUTES CONFLICT OF INTEREST QUESTIONNAIRES WHICH THE BOARD MEMBERS, OFFICERS, AND KEY EMPLOYEES COMPLETE AND RETURN. THE PRESIDENT AND VP OF FINANCE AND OPERATIONS REVIEW THE RETURNED FORMS FOR COMPLIANCE. IF A CONFLICT IS DISCOVERED IT IS ESCALATED TO THE APPROPRIATE PARTY WITHIN CALIBR AND THE PERSON RECUSES HIMSELF OR HERSELF FROM THE GOVERNING BODY'S DELILBERATIONS AND DECISIONS IN THE TRANSACTION. OFFICER COMPENSATION FORM 990, LINE 15A & 15B CALIBR'S BOARD OF DIRECTORS IS RESPONSIBLE FOR DETERMINING THE COMPENSATION OF THE PRESIDENT, AND UNDER THE GUIDANCE AND ADVICE FROM ATTORNEYS AND HUMAN RESOURCES, THE PRESIDENT AND THE BOARD OF DIRECTORS AGREED TO PAY THE PRESIDENT A SALARY APPROXIMATELY TWICE MINIMUM WAGE FOR THE YEAR ENDED AUGUST 31, 2013. THE PRESIDENT HAS WAIVED ANY OTHER FORMS OF COMPENSATION INCLUDING BONUSES AND NON-MONETARY BENEFITS AND PREQUISITES. Other officer salaries are determined by CALIBR'S President based on comparable salaries for individuals having similar roles and responsibilities at similar non-profits and biotech companies. PUBLIC DISCLOSURE OF GOVERNING DOCUMENTS PART VI, SECTION C, LINE 19 GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST.